Monthly
US$200
Billed every month
Levofloxacin and Sodium Chloride Injection(左氧氟沙星氯化钠注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders32View records ↓
Under-review filings14View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers49View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 32 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 32 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 北京百美特生物制药有限公司 | 山西诺成制药有限公司 | 国药准字H20255684 | 2025/10/14 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辽宁民康制药有限公司 | 辽宁民康制药有限公司 | 国药准字H20254813 | 2025/07/08 | 100ml∶左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都克莱蒙医药科技有限公司 | 四川科伦药业股份有限公司 | 国药准字H20254333 | 2025/05/27 | 50ml∶左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都克莱蒙医药科技有限公司 | 四川科伦药业股份有限公司 | 国药准字H20254335 | 2025/05/27 | 150ml∶左氧氟沙星（按C18H20FN3O4计）0.75g与氯化钠1.35g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都克莱蒙医药科技有限公司 | 四川科伦药业股份有限公司 | 国药准字H20254334 | 2025/05/27 | 100ml∶左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南爱科制药有限公司 | 海南爱科制药有限公司 | 国药准字H20254213 | 2025/05/20 | 100ml∶左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Not stated by source | CDE |
| 海南爱科制药有限公司 | 海南爱科制药有限公司 | 国药准字H20254212 | 2025/05/20 | 50ml∶左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东大翔制药有限公司 | 广东大翔制药有限公司 | 国药准字H20253438 | 2025/02/20 | 100ml∶左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药银湖制药有限公司 | 石药银湖制药有限公司 | 国药准字H20249701 | 2024/12/06 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏长江药业有限公司 | 江苏大红鹰恒顺药业有限公司 | 国药准字H20244645 | 2024/08/05 | 100ml∶左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北多瑞药业有限公司 | 宜昌三峡制药有限公司 | 国药准字H20244326 | 2024/06/28 | 100ml：左氧氟沙星（按C<sub>18</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 武汉福星生物药业有限公司 | 武汉福星生物药业有限公司 | 国药准字H20244174 | 2024/06/28 | 100ml∶左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 济川药业集团有限公司 | 哈尔滨三联药业股份有限公司 | 国药准字H20244087 | 2024/06/18 | 50ml∶左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 济川药业集团有限公司 | 哈尔滨三联药业股份有限公司 | 国药准字H20244086 | 2024/06/18 | 100ml∶左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北天成药业股份有限公司 | 河北天成药业股份有限公司 | 国药准字H20243017 | 2024/01/09 | 50ml:左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北天成药业股份有限公司 | 河北天成药业股份有限公司 | 国药准字H20243018 | 2024/01/09 | 100ml:左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 乐信乐美（海南）生物科技有限公司 | 西安京西双鹤药业有限公司 | 国药准字H20237156 | 2023/11/15 | 50ml：左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辰欣药业股份有限公司 | 辰欣药业股份有限公司 | 国药准字H20234286 | 2023/10/12 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 西安信百欣医药科技有限公司 | 湖南金健药业有限责任公司 | 国药准字H20234100 | 2023/09/08 | 50ml：左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 西安信百欣医药科技有限公司 | 湖南金健药业有限责任公司 | 国药准字H20234101 | 2023/09/08 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 哈尔滨三联药业股份有限公司 | 哈尔滨三联药业股份有限公司 | 国药准字H20233783 | 2023/06/27 | 100ml:左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 信合援生制药股份有限公司 | 信合援生制药股份有限公司 | 国药准字H20233765 | 2023/06/21 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 西安京西双鹤药业有限公司 | 西安京西双鹤药业有限公司 | 国药准字H20233725 | 2023/06/14 | 100ml:左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江莎普爱思药业股份有限公司 | 浙江莎普爱思药业股份有限公司 | 国药准字H20233466 | 2023/04/17 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 乐信乐美（海南）生物科技有限公司 | 西安京西双鹤药业有限公司 | 国药准字H20233234 | 2023/02/28 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华夏生生药业（北京）有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20237012 | 2023/02/03 | 50ml∶左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江医药股份有限公司新昌制药厂 | 浙江医药股份有限公司新昌制药厂 | 国药准字H20227162 | 2022/12/16 | 50ml：左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都医路康医学技术服务有限公司 | 四川绵竹鸿基制药有限责任公司 | 国药准字H20223903 | 2022/11/30 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 西南药业股份有限公司 | 西南药业股份有限公司 | 国药准字H20227101 | 2022/08/05 | 50ml:左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华润双鹤药业股份有限公司 | 华润双鹤药业股份有限公司 | 国药准字H20223352 | 2022/05/31 | 100ml:左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20223140 | 2022/03/16 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京恒道医药科技股份有限公司 | 江苏大红鹰恒顺药业有限公司 | 国药准字H20227030 | 2022/03/15 | 50ml：左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 扬子江药业集团江苏紫龙药业有限公司 | 扬子江药业集团有限公司 | 国药准字H20223095 | 2022/03/01 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京柏雅联合药物研究所有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20223087 | 2022/02/23 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华夏生生药业（北京）有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20217136 | 2021/12/21 | 50ml∶左氧氟沙星（按C18H20FN3O4计）0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江医药股份有限公司 | 浙江医药股份有限公司新昌制药厂 | 国药准字H20213725 | 2021/09/13 | 150ml：左氧氟沙星（按C18H20FN3O4计）0.75g与氯化钠1.35g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江医药股份有限公司 | 浙江医药股份有限公司新昌制药厂 | 国药准字H20213510 | 2021/06/18 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东赛烽医药科技有限公司 | 广州绿十字制药有限公司 | 国药准字H20213409 | 2021/05/19 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g。 | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 西南药业股份有限公司 | 西南药业股份有限公司 | 国药准字H20213249 | 2021/04/07 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华夏生生药业（北京）有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20213149 | 2021/02/24 | 100ml：左氧氟沙星（按C18H20FN3O4计）0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南科伦制药有限公司 | 湖南科伦制药有限公司 | 国药准字H20203719 | 2020/12/25 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南科伦制药有限公司 | 湖南科伦制药有限公司 | 国药准字H20203718 | 2020/12/25 | 50ml:左氧氟沙星(按C18H20FN3O4计)0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京恒道医药科技有限公司 | 福安药业集团宁波天衡制药有限公司 | 国药准字H20203495 | 2020/09/14 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20203477 | 2020/09/08 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20203476 | 2020/09/08 | 50ml:左氧氟沙星(按C18H20FN3O4计)0.25g与氯化钠0.45g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 49 distinct approval numbers and 32 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京吉洛华制药有限公司 | 国药准字H20020636 | 100ml:左氧氟沙星0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002010100226 | NHSA |
| 广州绿十字制药股份有限公司 | 国药准字H20213409 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g。 | Category B (乙) | XJ01MAZ083B002010100475 | NHSA |
| 西南药业股份有限公司 | 国药准字H20213249 | 100ml:左氧氟沙星0.5g(按C₁₈H₂₀FN₃O₄计)与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002010100978 | NHSA |
| 辽宁民康制药有限公司 | 国药准字H20254813 | 100ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002010101227 | NHSA |
| 成都医路康医学技术服务有限公司 | 国药准字H20223903 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002010102193 | NHSA |
| 西安信百欣医药科技有限公司 | 国药准字H20234100 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002010104936 | NHSA |
| 湖北多瑞药业有限公司 | 国药准字H20244326 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002010106652 | NHSA |
| 武汉福星生物药业有限公司 | 国药准字H20244174 | 100ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002010109598 | NHSA |
| 广东大翔制药有限公司 | 国药准字H20253439 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化钠0.45g | Category B (乙) | XJ01MAZ083B002010109938 | NHSA |
| 北京百美特生物制药有限公司 | 国药准字H20255684 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002010182359 | NHSA |
| 汕头经济特区明治医药有限公司 | 国药准字H20233234 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠 0.9g | Category B (乙) | XJ01MAZ083B002010183539 | NHSA |
| 成都克莱蒙医药科技有限公司 | 国药准字H20254333 | 50ml∶左氧氟沙星(按 C₁₈H₂₀FN₃O₄ 计)0.25g与氯化钠 0.45g | Category B (乙) | XJ01MAZ083B002010185240 | NHSA |
| 北京吉洛华制药有限公司 | 国药准字H20020636 | 100ml:左氧氟沙星0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002010200226 | NHSA |
| 广州绿十字制药股份有限公司 | 国药准字H20213409 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g。 | Category B (乙) | XJ01MAZ083B002010200475 | NHSA |
| 成都医路康医学技术服务有限公司 | 国药准字H20223903 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002010202193 | NHSA |
| 哈尔滨三联药业股份有限公司 | 国药准字H20233783 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002010203662 | NHSA |
| 武汉福星生物药业有限公司 | 国药准字H20244174 | 100ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002010209598 | NHSA |
| 汕头经济特区明治医药有限公司 | 国药准字H20233234 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠 0.9g | Category B (乙) | XJ01MAZ083B002010283539 | NHSA |
| 哈尔滨三联药业股份有限公司 | 国药准字H20233783 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002010303662 | NHSA |
| 汕头经济特区明治医药有限公司 | 国药准字H20233234 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠 0.9g | Category B (乙) | XJ01MAZ083B002010383539 | NHSA |
| 北京吉洛华制药有限公司 | 国药准字H20103722 | 150ml:左氧氟沙星0.75g与氯化钠1.35g | Category B (乙) | XJ01MAZ083B002020100226 | NHSA |
| 西南药业股份有限公司 | 国药准字H20227101 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002020100978 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20227030 | 50ml:左氧氟沙星(按C18H20FN3O4计)0.25g与氯化钠0.45g | Category B (乙) | XJ01MAZ083B002020101429 | NHSA |
| 重庆安诺生生命科技有限公司 | 国药准字H20244086 | 100ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002020101453 | NHSA |
| 西安京西双鹤药业有限公司 | 国药准字H20233725 | 100ml:左氧氟沙星( 按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002020102492 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20203495 | 100ml∶左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002020104561 | NHSA |
| 西安信百欣医药科技有限公司 | 国药准字H20234101 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002020104936 | NHSA |
| 海南爱科制药有限公司 | 国药准字H20254212 | 50ml∶左氧氟沙星(按 C₁₈H₂₀FN₃O₄计)0.25g与氯化钠 0.45g | Category B (乙) | XJ01MAZ083B002020105759 | NHSA |
| 广东大翔制药有限公司 | 国药准字H20253438 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002020109938 | NHSA |
| 汕头经济特区明治医药有限公司 | 国药准字H20237156 | 50ml:左氧氟沙星(按C18H20FN3O4计)0.25g与氯化钠0.45g | Category B (乙) | XJ01MAZ083B002020183539 | NHSA |
| 成都克莱蒙医药科技有限公司 | 国药准字H20254334 | 100ml∶左氧氟沙星(按 C₁₈H₂₀FN₃O₄ 计)0.5g与氯化钠 0.9g | Category B (乙) | XJ01MAZ083B002020185240 | NHSA |
| 西安京西双鹤药业有限公司 | 国药准字H20233725 | 100ml:左氧氟沙星( 按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002020202492 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20203495 | 100ml∶左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002020204561 | NHSA |
| 北京吉洛华制药有限公司 | 国药准字H20184116 | 50ml:左氧氟沙星0.25g与氯化钠0.45g | Category B (乙) | XJ01MAZ083B002030100226 | NHSA |
| 重庆安诺生生命科技有限公司 | 国药准字H20244087 | 50ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002030101453 | NHSA |
| 石药银湖制药有限公司 | 国药准字H20249701 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002030102964 | NHSA |
| 信合援生制药股份有限公司 | 国药准字H20233765 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002030103140 | NHSA |
| 海南爱科制药有限公司 | 国药准字H20254213 | 100ml∶左氧氟沙星(按 C₁₈H₂₀FN₃O₄计)0.5g与氯化钠 0.9g | Category B (乙) | XJ01MAZ083B002030105759 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20223352 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002030181661 | NHSA |
| 成都克莱蒙医药科技有限公司 | 国药准字H20254335 | 150ml∶左氧氟沙星(按 C₁₈H₂₀FN₃O₄ 计)0.75g与氯化钠 1.35g | Category B (乙) | XJ01MAZ083B002030185240 | NHSA |
| 信合援生制药股份有限公司 | 国药准字H20233765 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002030203140 | NHSA |
| 湖南科伦制药有限公司 | 国药准字H20203718 | 50ml:左氧氟沙星(按C18H20FN3O4计)0.25g与氯化钠0.45g | Category B (乙) | XJ01MAZ083B002040104948 | NHSA |
| 浙江医药股份有限公司新昌制药厂 | 国药准字H20213510 | 100ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002040107968 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20213149 | 100ml∶左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002040109910 | NHSA |
| 浙江医药股份有限公司新昌制药厂 | 国药准字H20213510 | 100ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002040207968 | NHSA |
| 江苏长江药业有限公司 | 国药准字H20244645 | 100ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002050101426 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243017 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002050102662 | NHSA |
| 石家庄四药有限公司 | 国药准字H20223140 | 100ml:左氧氟沙星0.5g(按C18H20FN3O4计)与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002050102763 | NHSA |
| 湖南科伦制药有限公司 | 国药准字H20203719 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002050104948 | NHSA |
| 浙江医药股份有限公司新昌制药厂 | 国药准字H20213725 | 150ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.75g与氯化 | Category B (乙) | XJ01MAZ083B002050107968 | NHSA |
| 北京六环药业有限公司 | 国药准字H20217136 | 50ml∶左氧氟沙星(按C18H20FN3O4计)0.25g与氯化钠0.45g | Category B (乙) | XJ01MAZ083B002050109910 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243017 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002050202662 | NHSA |
| 石家庄四药有限公司 | 国药准字H20223140 | 100ml:左氧氟沙星0.5g(按C18H20FN3O4计)与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002050202763 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243017 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002050302662 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243017 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002050402662 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243018 | 100ml:左氧氟沙星(按C18H20FN3O4)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060102662 | NHSA |
| 浙江医药股份有限公司新昌制药厂 | 国药准字H20227162 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002060107968 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243018 | 100ml:左氧氟沙星(按C18H20FN3O4)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060202662 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243018 | 100ml:左氧氟沙星(按C18H20FN3O4)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060302662 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243018 | 100ml:左氧氟沙星(按C18H20FN3O4)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060402662 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20213149 | 100ml∶左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060509910 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20213149 | 100ml∶左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060609910 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20213149 | 100ml∶左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060709910 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20213149 | 100ml∶左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060809910 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20213149 | 100ml∶左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002060909910 | NHSA |
| 扬子江药业集团有限公司 | 国药准字H20223095 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002070101749 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20234286 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002070104127 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20233466 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002070104693 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20237012 | 50ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002070109910 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20237012 | 50ml∶左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002070209910 | NHSA |
| 北京柏雅联合药物研究所有限公司 | 国药准字H20223087 | 100ml:左氧氟沙星(按C18H20FN3O4计)0.5g与氯化钠0.9g | Category B (乙) | XJ01MAZ083B002090102189 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20203476 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002090104145 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20203476 | 50ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.25g与氯化 | Category B (乙) | XJ01MAZ083B002090204145 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20203477 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002100104145 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20203477 | 100ml:左氧氟沙星(按C₁₈H₂₀FN₃O₄计)0.5g与氯化 | Category B (乙) | XJ01MAZ083B002100204145 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 14 filings and 8 distinct first applicants.
Supplement 6 · Generic 8
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏长江药业有限公司;江苏大红鹰恒顺药业有限公司 | CYHB2601543 | Supplement | 2026/08/13 | Not stated by source | CDE |
| 石药银湖制药有限公司 | CYHB2601220 | Supplement | 2026/06/30 | Not stated by source | CDE |
| 浙江康吉尔药业有限公司 | CYHS2601182 | Generic | 2026/05/20 | Not stated by source | CDE |
| 浙江康吉尔药业有限公司 | CYHS2601181 | Generic | 2026/05/20 | Not stated by source | CDE |
| 河南利欣制药股份有限公司 | CYHS2601021 | Generic | 2026/05/01 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHB2600351 | Supplement | 2026/02/13 | Not stated by source | CDE |
| 广东科泓药业有限公司 | CYHS2600407 | Generic | 2026/02/07 | Not stated by source | CDE |
| 广东科泓药业有限公司 | CYHS2600406 | Generic | 2026/02/07 | Not stated by source | CDE |
| 广东科泓药业有限公司 | CYHS2600405 | Generic | 2026/02/07 | Not stated by source | CDE |
| 重庆安诺生生命科技有限公司;哈尔滨三联药业股份有限公司 | CYHB2501920 | Supplement | 2025/09/28 | Not stated by source | CDE |
| 重庆安诺生生命科技有限公司;哈尔滨三联药业股份有限公司 | CYHB2501919 | Supplement | 2025/09/28 | Not stated by source | CDE |
| 重庆安诺生生命科技有限公司;哈尔滨三联药业股份有限公司 | CYHB2501918 | Supplement | 2025/09/28 | Not stated by source | CDE |
| 浙江国镜药业有限公司;四川科伦药业股份有限公司 | CYHS2503303 | Generic | 2025/09/06 | Not stated by source | CDE |
| 浙江国镜药业有限公司;四川科伦药业股份有限公司 | CYHS2503302 | Generic | 2025/09/06 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 6 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江康吉尔药业有限公司 | CYHS2601182 | Generic | 2026/05/20 | Not stated by source | CDE |
| 浙江康吉尔药业有限公司 | CYHS2601181 | Generic | 2026/05/20 | Not stated by source | CDE |
| 河南利欣制药股份有限公司 | CYHS2601021 | Generic | 2026/05/01 | Not stated by source | CDE |
| 广东科泓药业有限公司 | CYHS2600407 | Generic | 2026/02/07 | Not stated by source | CDE |
| 广东科泓药业有限公司 | CYHS2600406 | Generic | 2026/02/07 | Not stated by source | CDE |
| 广东科泓药业有限公司 | CYHS2600405 | Generic | 2026/02/07 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/08/13Accepted
江苏长江药业有限公司;江苏大红鹰恒顺药业有限公司
CYHB2601543
Fact date: 2026/08/13 · Site observation date: 2026/10/21
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Levofloxacin and Sodium Chloride Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy